Physician profile
Markus Ploesser
NPI 1669662755
$156,913.98
in general payments reported to CMS, 2019-2025
22 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $16K · 2021: $5,221 · 2022: $11K · 2023: $41K · 2024: $35K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Food and Beverage: $11K · Consulting Fee: $7,460 · Travel and Lodging: $4,390 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,270.00 |
| Food and Beverage | $10,669.09 |
| Consulting Fee | $7,460.00 |
| Travel and Lodging | $4,390.30 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $59,819.76 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $52,359.82 | 2019-2025 | Uzedy |
| Indivior INC. | $33,903.35 | 2019-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $2,536.53 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,942.58 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,928.61 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $995.91 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $840.80 | 2023-2024 | Auvelity |
| Abbvie INC. | $467.89 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $400.16 | 2019-2025 | Fanapt |
| Medtronic, INC. | $348.91 | 2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $283.75 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $179.63 | 2019-2022 | |
| Avanos Medical | $163.09 | 2025 | Coolief Cooled Radiofrequency |
| Boston Scientific Corporation | $161.98 | 2025 | General - Pain Management |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $148.96 | 2022 | |
| Abbott Laboratories | $146.57 | 2025 | Eterna |
| Acadia Pharmaceuticals INC | $119.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $84.97 | 2022 | |
| Neuronetics, INC. | $36.19 | 2023-2025 | Neurostar Tms Therapy System |
| Spr Therapeutics, INC | $24.11 | 2025 | Sprint Pns System |
| Braeburn INC. | $21.22 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markus Ploesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.